메뉴 건너뛰기




Volumn 6, Issue 2, 2012, Pages 27-29

Biosimilars in oncology: Emerging and future benefits

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

EID: 84876431319     PISSN: 17833914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (3)

References (22)
  • 2
    • 80053238941 scopus 로고    scopus 로고
    • Delivering affordable cancer care in high-income countries
    • Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-80.
    • (2011) Lancet Oncol. , vol.12 , Issue.10 , pp. 933-980
    • Sullivan, R.1    Peppercorn, J.2    Sikora, K.3
  • 3
    • 84864367909 scopus 로고    scopus 로고
    • Global cancer transitions according to the Human Development Index (2008-2030): A population-based study
    • Aug, doi: 10.1016/S1470-2045(12)70211-5
    • Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5.
    • (2012) Lancet Oncol. , vol.13 , Issue.8 , pp. 790-801
    • Bray, F.1    Jemal, A.2    Grey, N.3    Ferlay, J.4    Forman, D.5
  • 6
    • 81355158511 scopus 로고    scopus 로고
    • Time to consider cost in evaluating cancer drugs in United States?
    • 14 July, [cited 2012 Aug 26]. Available from
    • Mulcahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape News, 14 July 2009 [cited 2012 Aug 26]. Available from: http://www.medscape.com/viewarticle/705689
    • (2009) Medscape News
    • Mulcahy, N.1
  • 7
    • 79959653044 scopus 로고    scopus 로고
    • Therapeutic decision making in oncology
    • Perrin S. Therapeutic decision making in oncology. Hosp Pharm Europe. 2010; 52:36-7.
    • (2010) Hosp Pharm Europe. , vol.52 , pp. 36-37
    • Perrin, S.1
  • 8
    • 80051490700 scopus 로고    scopus 로고
    • Biosimilars: Are they ready for primetime in the United States?
    • Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011;9(8):934-3.
    • (2011) J Natl Compr Canc Netw. , vol.9 , Issue.8 , pp. 934-943
    • Hirsch, B.R.1    Lyman, G.H.2
  • 10
    • 33846974021 scopus 로고    scopus 로고
    • Cost of cancer care: Issues and implications
    • Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;10:180-6.
    • (2007) J Clin Oncol. , vol.10 , pp. 180-186
    • Meropol, N.J.1    Schulman, K.A.2
  • 11
    • 80051984166 scopus 로고    scopus 로고
    • Biosimilars of biological drug therapies: Regulatory, clinical and commercial considerations
    • Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71:1527-36.
    • (2011) Drugs. , vol.71 , pp. 1527-1536
    • Dranitsaris, G.1    Amir, E.2    Dorward, K.3
  • 12
    • 79952973241 scopus 로고    scopus 로고
    • Biosimilar medicines and cost-effectiveness
    • Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29-36.
    • (2011) Clinicoecon Outcomes Res. , vol.3 , pp. 29-36
    • Simoens, S.1
  • 13
    • 79952923217 scopus 로고    scopus 로고
    • The future of biosimilars
    • Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010;49:33-4.
    • (2010) Hosp Pharm Europe. , vol.49 , pp. 33-34
    • Mellstedt, H.1
  • 14
  • 16
    • 84871355839 scopus 로고    scopus 로고
    • Comparative cost-effectiveness across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia
    • Aapro M, Cornes P, Abraham I. Comparative cost-effectiveness across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Practice. 2012;18:171-9.
    • (2012) J Oncol Pharm Practice. , vol.18 , pp. 171-179
    • Aapro, M.1    Cornes, P.2    Abraham, I.3
  • 17
    • 84864487642 scopus 로고    scopus 로고
    • Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
    • May
    • Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012 May;4(3):95-105.
    • (2012) Ther Adv Med Oncol. , vol.4 , Issue.3 , pp. 95-105
    • Aapro, M.1    Cornes, P.2    Sun, D.3    Abraham, I.4
  • 18
    • 84876455323 scopus 로고    scopus 로고
    • Biosimilar medicines in oncology: Single-center experience with biosimilar G-CSF
    • Salesi N, Di Cocco B, Veltri E. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. J Clin Oncol. 2012;30(suppl):abstr e19501.
    • (2012) J Clin Oncol. , vol.30 , Issue.SUPPL.
    • Salesi, N.1    Di Cocco, B.2    Veltri, E.3
  • 19
    • 84857903642 scopus 로고    scopus 로고
    • What do prescribers think of biosimilars?
    • Aapro M. What do prescribers think of biosimilars? Target Oncol. 2012;7 Suppl 1:S51-S55.
    • (2012) Target Oncol. , vol.7 , Issue.SUPPL. 1
    • Aapro, M.1
  • 20
    • 81355123577 scopus 로고    scopus 로고
    • Biosimilars: What they are and their use in oncology
    • Grande E, Carrato A. Biosimilars: what they are and their use in oncology. Cancer Chemother Rev. 2011;6:23-30.
    • (2011) Cancer Chemother Rev. , vol.6 , pp. 23-30
    • Grande, E.1    Carrato, A.2
  • 21
    • 84857905655 scopus 로고    scopus 로고
    • The economic pressures for biosimilar drug use in cancer medicine
    • Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012 7 Suppl 1:S57-S67
    • (2012) Target Oncol. , vol.7 , Issue.SUPPL. 1
    • Cornes, P.1
  • 22
    • 78751635955 scopus 로고    scopus 로고
    • European Medicines Agency, London, UK: [cited 2012 Aug 26]. Available from
    • European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies. London, UK: 2010 [cited 2012 Aug 26]. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2010/11/WC500 099361.pdf
    • (2010) Guideline on similar biological medicinal products containing monoclonal antibodies


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.